Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IDEAYA Biosciences, Inc. (IDYA)
USD36.66
+0.01 (+0.03%)
US NASDAQ Healthcare Biotechnology
Address
7000 Shoreline Court 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Yujiro S. Hata
Website
ideayabio.com
IPO
2019-05-23
CIK 1676725 ISIN US45166A1025
Description
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD36.66
+0.01 (+0.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
-0.05
Float Shares
86.96M
Free Float %
99.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04% | -0.04% | -7.80% | -10.79% | -11.99% | -18.66% | +53.24% | +31.40% | +45.40% | +151.30% | +151.30% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (25 ratings, all time)
Buy
Price Targets & DCF
Current price
36.66
Low
53.00
+44.6%
Consensus
58.67
+60.0%
Median
58.00
+58.2%
High
65.00
+77.3%
Ratings Trend (MoM)
89% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 13 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 3 |
58.67
+60.0%
|
| Last Quarter | 4 |
57.00
+55.5%
|
| Last Year | 14 |
47.71
+30.1%
|
| All Time | 30 |
47.60
+29.8%
|
Quality scores
Altman Z-Score
15.16
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+3,024.4% ★
-
EPS growth Biotechnology: +29.7%+61.9% ★ Q1'26: -35.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-71.0% Q1'26: -1,160.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-72.8% Q1'26: -1,654.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-38.7% Q1'26: -147.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+8.3% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.18× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 12 EPS Ana. |
Dec 2027 11 Rev. Ana. 12 EPS Ana. |
Dec 2028 12 Rev. Ana. 10 EPS Ana. |
Dec 2029 11 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.54M
est: 16.91M (+15.5%)
|
27.94M
est: 33.97M (-17.7%)
|
50.93M
est: 53.92M (-5.5%)
|
23.39M
est: 11.96M (+95.5%)
|
7.00M
est: 4.67M (+50.0%)
|
218.71M
est: 216.88M (+0.8%)
|
34.69M
5.87M – 56.05M
-84.0% YoY
|
115.22M
23.23M – 165.71M
+232.2% YoY
|
267.84M
264.74M – 270.95M
+132.5% YoY
|
584.89M
102.22M – 1.05B
+118.4% YoY
|
1.03B
179.34M – 1.84B
+75.5% YoY
|
| EBITDA |
-33.11M
est: -16.91M (-95.8%)
|
-48.04M
est: -33.97M (-41.4%)
|
-56.55M
est: -53.92M (-4.9%)
|
-108.95M
est: -11.26M (-867.5%)
|
-270.64M
est: -4.39M (-6,059.8%)
|
-154.72M
est: -204.19M (+24.2%)
|
-32.66M
-52.77M – -5.53M
+84.0% YoY
|
-108.48M
-156.01M – -21.87M
-232.2% YoY
|
-252.17M
-255.09M – -249.24M
-132.5% YoY
|
-550.67M
-989.27M – -96.24M
-118.4% YoY
|
-966.15M
-1.74B – -168.85M
-75.5% YoY
|
| EBIT |
-34.50M
est: -16.91M (-104.0%)
|
-49.76M
est: -33.97M (-46.5%)
|
-58.66M
est: -53.92M (-8.8%)
|
-112.96M
est: -11.31M (-898.7%)
|
-274.48M
est: -4.41M (-6,119.4%)
|
-159.31M
est: -205.10M (+22.3%)
|
-32.81M
-53.01M – -5.56M
+84.0% YoY
|
-108.97M
-156.71M – -21.96M
-232.2% YoY
|
-253.29M
-256.23M – -250.36M
-132.5% YoY
|
-553.12M
-993.68M – -96.67M
-118.4% YoY
|
-970.46M
-1.74B – -169.60M
-75.5% YoY
|
| Net Income |
-34.50M
est: -116.53M (+70.4%)
|
-49.76M
est: -100.27M (+50.4%)
|
-58.66M
est: -143.58M (+59.1%)
|
-112.96M
est: -153.74M (+26.5%)
|
-274.48M
est: -217.38M (-26.3%)
|
-113.70M
est: -102.40M (-11.0%)
|
-403.75M
-437.82M – -299.42M
-294.3% YoY
|
-377.99M
-389.99M – -109.60M
+6.4% YoY
|
-320.96M
-328.24M – -190.84M
+15.1% YoY
|
-69.31M
-141.08M – 5.05M
+78.4% YoY
|
187.98M
-13.69M – 382.63M
+371.2% YoY
|
| SGA |
13.80M
est: 26.70M (-48.3%)
|
18.33M
est: 53.64M (-65.8%)
|
21.80M
est: 85.14M (-74.4%)
|
24.30M
est: 17.89M (+35.8%)
|
35.47M
est: 6.98M (+408.1%)
|
63.32M
est: 324.42M (-80.5%)
|
51.89M
8.79M – 83.85M
-84.0% YoY
|
172.36M
34.74M – 247.87M
+232.2% YoY
|
400.65M
396.01M – 405.30M
+132.5% YoY
|
874.91M
152.90M – 1.57B
+118.4% YoY
|
1.54B
268.27M – 2.76B
+75.5% YoY
|
| EPS |
-1.31
est: -1.43 (+8.2%)
|
-1.41
est: -1.23 (-14.9%)
|
-1.42
est: -1.43 (+1.0%)
|
-1.96
est: -2.21 (+11.2%)
|
-3.36
est: -2.47 (-36.2%)
|
-1.28
est: -1.29 (+0.5%)
|
-4.38
-4.95 – -3.38
-240.0% YoY
|
-3.74
-4.41 – -1.24
+14.4% YoY
|
-2.90
-3.71 – -2.16
+22.6% YoY
|
-0.78
-1.59 – 0.06
+73.0% YoY
|
2.12
-0.15 – 4.32
+371.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-07 | Mizuho | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-89.00M
OE per share TTM
-1.03
Owner's Yield
-3.57%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
30.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
34
Total invested
40.84M
Insider transactions (90d)
0
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 8.16M | 11.07% | — | — | 8.16M | — | IN | United States of America | 2024-02-12 | ↗ |
| 2 | FMR LLC | 8.16M | 11.07% | 8.16M | — | 8.16M | — | HC | Delaware | 2024-02-12 | ↗ |
| 3 | 52-0556948 | 3.57M | 5.50% | 705.4K | — | 3.57M | — | IA | Maryland | 2024-02-14 | ↗ |
| 4 | EIN #00-0000000 | 3.55M | 5.50% | — | 3.55M | — | 3.55M | IA, HC | Jersey, Channel Islands | 2024-02-14 | ↗ |
| 5 | The Vanguard Group - 23-1945930 | 3.48M | 5.39% | — | — | 3.34M | 134.5K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 6 | Arsani William | 2.65M | 11.00% | — | — | — | 2.65M | HC, IN | Delaware | 2022-03-18 | ↗ |
| 7 | Logos GP LLC | 2.65M | 11.00% | — | — | — | 2.65M | OO | Delaware | 2022-03-18 | ↗ |
| 8 | Logos Global Management GP LLC | 2.65M | 11.00% | — | — | — | 2.65M | HC, OO | Delaware | 2022-03-18 | ↗ |
| 9 | Logos Global Management LP | 2.65M | 11.00% | — | — | — | 2.65M | IA, PN | Delaware | 2022-03-18 | ↗ |
| 10 | Logos Global Master Fund LP | 2.65M | 11.00% | — | — | — | 2.65M | PN | Delaware | 2022-03-18 | ↗ |
| 11 | Adage Capital Advisors, L.L.C. | 2.60M | 5.41% | — | 2.60M | — | — | OO | Delaware | 2023-02-27 | ↗ |
| 12 | Adage Capital Partners GP, L.L.C. | 2.60M | 5.41% | — | 2.60M | — | — | OO | Delaware | 2023-02-27 | ↗ |
| 13 | Adage Capital Partners, L.P. | 2.60M | 5.41% | — | 2.60M | — | — | PN | Delaware | 2023-02-27 | ↗ |
| 14 | Phillip Gross | 2.60M | 5.41% | — | 2.60M | — | — | IN | United States | 2023-02-27 | ↗ |
| 15 | Robert Atchinson | 2.60M | 5.41% | — | 2.60M | — | — | IN | United States | 2023-02-27 | ↗ |
| 16 | Avidity Capital Partners (GP) LLC | 2.55M | 6.60% | — | 2.55M | — | 2.55M | OO | Delaware | 2022-02-14 | ↗ |
| 17 | BVF Inc. | 2.46M | 5.10% | — | — | — | 2.46M | CO | Delaware | 2023-03-24 | ↗ |
| 18 | BVF Partners L.P. | 2.46M | 5.10% | — | — | — | 2.46M | IA, PN | Delaware | 2023-03-24 | ↗ |
| 19 | Mark N. Lampert | 2.46M | 5.10% | — | — | — | 2.46M | IN | Delaware | 2023-03-24 | ↗ |
| 20 | BVF GP Holdings LLC | 2.31M | 4.80% | — | — | — | 2.31M | OO | Delaware | 2023-03-24 | ↗ |
| 21 | J. Christopher Donahue | 2.29M | 5.95% | — | 2.29M | — | 2.29M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 22 | Rhodora J. Donahue | 2.29M | 5.95% | — | 2.29M | — | 2.29M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 23 | Thomas R. Donahue | 2.29M | 5.95% | — | 2.29M | — | 2.29M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 24 | Steven A. Cohen | 2.05M | 4.00% | — | 2.05M | — | 2.05M | IN | Delaware | 2022-02-18 | ↗ |
| 25 | Point72 Asset Management, L.P. | 2.05M | 4.00% | — | 2.05M | — | 2.05M | PN | Delaware | 2022-02-18 | ↗ |
| 26 | Point72 Capital Advisors, Inc. | 2.05M | 4.00% | — | 2.05M | — | 2.05M | CO | Delaware | 2022-02-18 | ↗ |
| 27 | Avidity Master Fund LP | 2.04M | 5.30% | — | 2.04M | — | 2.04M | PN, OO | Delaware | 2022-02-14 | ↗ |
| 28 | Biotechnology Value Fund, L.P. | 1.31M | 2.70% | — | — | — | 1.31M | PN | Delaware | 2023-03-24 | ↗ |
| 29 | BVF I GP LLC | 1.06M | 2.80% | — | — | — | 1.06M | OO | Delaware | 2022-05-02 | ↗ |
| 30 | BVF II GP LLC | 996.1K | 2.10% | — | — | — | 996.1K | OO | Delaware | 2023-03-24 | ↗ |
| 31 | Biotechnology Value Fund II, L.P. | 996.1K | 2.10% | — | — | — | 996.1K | PN | Delaware | 2023-03-24 | ↗ |
| 32 | BVF Partners OS Ltd. | 112.7K | 1.00% | — | — | — | 112.7K | CO | Delaware | 2023-03-24 | ↗ |
| 33 | Biotechnology Value Trading Fund OS LP | 112.7K | 1.00% | — | — | — | 112.7K | PN | Delaware | 2023-03-24 | ↗ |
| 34 | Cubist Systematic Strategies, LLC | 2.2K | 4.00% | — | 2.2K | — | 2.2K | OO | Delaware | 2022-02-18 | ↗ |
| 35 | Point72 Hong Kong Limited | 1.8K | 4.00% | — | 1.8K | — | 1.8K | OO | Delaware | 2022-02-18 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
34
-218 vs prev Q
New positions
3
Closed positions
213
Increased
11
Reduced
9
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 13.15M +3.4K (+0.0%) | 454.59M +96.9M (+27.1%) | 14.67% -0.193 pp | 0.02% +0.005 pp | USD38.72 -10.7% | 20 qtrs — |
| 2 | BLACKROCK, INC. | 8.21M +82.2K (+1.0%) | 283.80M +62.7M (+28.3%) | 9.28% +0.092 pp | 0.00% +0.001 pp | USD29.97 +15.3% | 6 qtrs — |
| 3 | JANUS HENDERSON GROUP PLC | 7.19M +758.1K (+11.8%) | 248.34M +73.4M (+42.0%) | 8.02% +0.750 pp | 0.11% +0.031 pp | USD29.21 +18.3% | 18 qtrs — |
| 4 | CAPITAL RESEARCH GLOBAL INVESTORS | 5.28M -1.3M (-19.4%) | 182.52M +4.2M (+2.4%) | 5.89% -1.518 pp | 0.03% +0.000 pp | USD24.18 +43.0% | 11 qtrs — |
| 5 | VANGUARD GROUP INC | 5.02M +97.1K (+2.0%) | 173.52M +39.6M (+29.6%) | 5.67% +0.109 pp | 0.00% +0.001 pp | USD26.08 +32.6% | 27 qtrs — |
| 6 | STATE STREET CORP | 4.13M +893.7K (+27.6%) | 142.93M +54.7M (+62.1%) | 4.67% +1.010 pp | 0.00% +0.002 pp | USD27.71 +24.8% | 23 qtrs — |
| 7 | BAKER BROS. ADVISORS LP | 3.62M +343.4K (+10.5%) | 125.10M +36.0M (+40.4%) | 4.09% +0.388 pp | 0.73% +0.089 pp | USD23.04 +50.0% | 14 qtrs — |
| 8 | FEDERATED HERMES, INC. | 3.40M -1.2M (-26.6%) | 117.39M -8.5M (-6.7%) | 3.79% -1.441 pp | 0.20% -0.026 pp | USD25.91 +33.4% | 22 qtrs — |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.80M -100.1K (-3.5%) | 96.80M +17.9M (+22.7%) | 3.16% -0.114 pp | 0.15% +0.022 pp | USD24.53 +40.9% | 20 qtrs — |
| 10 | FIERA CAPITAL CORP | 2.44M +599.3K (+32.6%) | 84.26M +34.2M (+68.5%) | 2.72% +0.641 pp | 0.27% +0.106 pp | USD34.94 -1.1% | 8 qtrs — |
| 11 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.15M +— (+0.0%) | 74.43M +15.8M (+27.0%) | 2.43% 0.000 pp | 0.95% +0.056 pp | USD21.08 +64.0% | 14 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 2.07M -76.5K (-3.6%) | 71.69M +13.2M (+22.5%) | 2.34% -0.087 pp | 0.00% +0.001 pp | USD26.31 +31.4% | 23 qtrs — |
| 13 | POINT72 ASSET MANAGEMENT, L.P. | 1.84M -2.0M (-51.7%) | 63.77M -40.1M (-38.6%) | 2.06% -2.256 pp | 0.07% -0.102 pp | USD20.89 +65.5% | 4 qtrs — |
| 14 | GOLDMAN SACHS GROUP INC | 1.77M +537.8K (+43.6%) | 61.22M +27.7M (+82.5%) | 1.98% +0.581 pp | 0.01% +0.003 pp | USD28.54 +21.1% | 27 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.45M +339.4K (+30.6%) | 50.10M +19.9M (+65.9%) | 1.64% +0.383 pp | 0.01% +0.002 pp | USD29.28 +18.1% | 21 qtrs — |
| 16 | GSK PLC | 1.33M +1.3M (+100.0%) | 46.09M +46.1M (+100.0%) | 1.49% +1.487 pp | 5.77% +5.769 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 17 | MORGAN STANLEY | 1.25M -327.9K (-20.8%) | 43.30M +294.2K (+0.7%) | 1.42% -0.371 pp | 0.00% +0.000 pp | USD26.58 +30.1% | 25 qtrs — |
| 18 | UBS GROUP AG | 1.09M +29.1K (+2.7%) | 37.53M +8.8M (+30.5%) | 1.23% +0.033 pp | 0.01% +0.002 pp | USD26.10 +32.5% | 26 qtrs — |
| 19 | CANDRIAM S.C.A. | 1.03M +18.4K (+1.8%) | 35.66M +8.1M (+29.4%) | 1.15% +0.005 pp | 0.18% +0.033 pp | USD28.38 +21.8% | 14 qtrs — |
| 20 | ENSIGN PEAK ADVISORS, INC | 979.1K +225.9K (+30.0%) | 33.85M +13.4M (+65.2%) | 1.09% +0.241 pp | 0.06% +0.026 pp | USD26.45 +30.7% | 22 qtrs — |
| 21 | CITADEL ADVISORS LLC | 959.4K -357.6K (-27.2%) | 33.16M -2.7M (-7.5%) | 1.08% -0.404 pp | 0.01% -0.001 pp | USD25.24 +37.0% | 16 qtrs — |
| 22 | DIMENSIONAL FUND ADVISORS LP | 938.9K +441.8K (+88.9%) | 32.46M +18.9M (+140.0%) | 1.05% +0.485 pp | 0.01% +0.004 pp | USD29.54 +17.0% | 18 qtrs — |
| 23 | BANK OF AMERICA CORP /DE/ | 903.0K -13.1K (-1.4%) | 31.22M +6.3M (+25.2%) | 1.02% -0.015 pp | 0.00% +0.001 pp | USD27.14 +27.4% | 24 qtrs — |
| 24 | FISHER ASSET MANAGEMENT, LLC | 889.6K +27.4K (+3.2%) | 30.75M +7.3M (+31.1%) | 0.99% +0.018 pp | 0.01% +0.002 pp | USD33.39 +3.5% | 11 qtrs — |
| 25 | SOFINNOVA INVESTMENTS, INC. | 885.1K -37.6K (-4.1%) | 30.60M +5.5M (+21.9%) | 0.99% -0.056 pp | 1.32% -0.054 pp | USD21.81 +58.5% | 14 qtrs — |
| 26 | REDMILE GROUP, LLC | 742.0K +— (+0.0%) | 25.65M +5.5M (+27.0%) | 0.83% -0.011 pp | 1.89% -0.075 pp | USD32.09 +7.7% | 9 qtrs — |
| 27 | PICTET ASSET MANAGEMENT HOLDING SA | 734.3K -298.7K (-28.9%) | 25.39M -2.7M (-9.7%) | 0.82% -0.349 pp | 0.02% -0.002 pp | USD36.20 -4.5% | 9 qtrs — |
| 28 | FIRST TURN MANAGEMENT, LLC | 723.7K +723.7K (+100.0%) | 25.02M +25.0M (+100.0%) | 0.81% +0.807 pp | 2.86% +2.858 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 714.6K -905.0 (-0.1%) | 24.70M +5.2M (+26.9%) | 0.80% -0.012 pp | 0.00% +0.001 pp | USD28.52 +21.2% | 23 qtrs — |
| 30 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 697.9K +289.5K (+70.9%) | 24.13M +13.0M (+117.1%) | 0.78% +0.317 pp | 0.03% -0.001 pp | USD30.26 +14.2% | 3 qtrs — |
| 31 | NORTHERN TRUST CORP | 675.1K -34.7K (-4.9%) | 23.34M +4.0M (+20.8%) | 0.75% -0.049 pp | 0.00% +0.001 pp | USD23.48 +47.2% | 23 qtrs — |
| 32 | BALYASNY ASSET MANAGEMENT L.P. | 596.5K +216.2K (+56.8%) | 20.62M +10.3M (+99.3%) | 0.67% +0.235 pp | 0.03% +0.013 pp | USD29.48 +17.3% | 6 qtrs — |
| 33 | ABRDN PLC | 560.6K +2.6K (+0.5%) | 19.38M +4.2M (+27.6%) | 0.63% -0.006 pp | 0.03% +0.006 pp | USD26.30 +31.4% | 6 qtrs — |
| 34 | NEW YORK STATE COMMON RETIREMENT FUND | 508.3K +19.4K (+4.0%) | 17.57M +4.3M (+32.1%) | 0.57% +0.014 pp | 0.02% +0.006 pp | USD34.80 -0.7% | 23 qtrs — |
| 35 | DAFNA CAPITAL MANAGEMENT LLC | 506.7K -33.2K (-6.1%) | 17.52M +2.8M (+19.2%) | 0.57% -0.045 pp | 4.07% +0.440 pp | USD18.58 +86.1% | 22 qtrs — |
| 36 | QUBE RESEARCH & TECHNOLOGIES LTD | 467.9K +204.2K (+77.4%) | 16.17M +9.0M (+125.4%) | 0.52% +0.224 pp | 0.02% +0.009 pp | USD31.21 +10.8% | 12 qtrs — |
| 37 | IRON TRIANGLE PARTNERS LP | 467.5K +197.5K (+73.1%) | 16.16M +8.8M (+120.0%) | 0.52% +0.216 pp | 1.85% +0.803 pp | USD30.32 +14.0% | 2 qtrs — |
| 38 | LOGOS GLOBAL MANAGEMENT LP | 450.0K +— (+0.0%) | 15.56M +3.3M (+27.0%) | 0.50% -0.007 pp | 0.94% -0.158 pp | USD27.21 +27.0% | 2 qtrs — |
| 39 | CAPTION MANAGEMENT, LLC | 450.0K +450.0K (+100.0%) | 15.56M +15.6M (+100.0%) | 0.51% +0.509 pp | 0.11% +0.107 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 40 | TANG CAPITAL MANAGEMENT LLC | 450.0K +50.0K (+12.5%) | 15.56M +4.7M (+42.9%) | 0.51% +0.056 pp | 0.77% +0.350 pp | USD28.03 +23.3% | 2 qtrs — |
| 41 | NUVEEN, LLC | 374.0K +165.2K (+79.2%) | 12.93M +7.2M (+127.6%) | 0.42% +0.187 pp | 0.00% +0.002 pp | USD24.42 +41.6% | 4 qtrs — |
| 42 | DEUTSCHE BANK AG\ | 368.5K -37.2K (-9.2%) | 12.74M +1.7M (+15.4%) | 0.41% -0.048 pp | 0.00% +0.000 pp | USD33.09 +4.5% | 23 qtrs — |
| 43 | JPMORGAN CHASE & CO | 299.9K +125.6K (+72.1%) | 10.37M +5.6M (+118.6%) | 0.33% +0.138 pp | 0.00% +0.000 pp | USD27.74 +24.6% | 23 qtrs — |
| 44 | EVENTIDE ASSET MANAGEMENT, LLC | 284.1K -341.6K (-54.6%) | 9.82M -7.2M (-42.3%) | 0.32% -0.390 pp | 0.15% -0.127 pp | USD26.26 +31.6% | 10 qtrs — |
| 45 | GENERAL AMERICAN INVESTORS CO INC | 280.3K +— (+0.0%) | 9.69M +2.1M (+27.0%) | 0.31% -0.004 pp | 0.55% +0.105 pp | USD23.07 +49.8% | 6 qtrs — |
| 46 | ENVESTNET ASSET MANAGEMENT INC | 277.6K -21.5K (-7.2%) | 9.60M +1.5M (+17.9%) | 0.31% -0.024 pp | 0.00% +0.001 pp | USD31.40 +10.1% | 8 qtrs — |
| 47 | WELLS FARGO & COMPANY/MN | 256.1K +13.1K (+5.4%) | 8.85M +2.2M (+33.9%) | 0.29% +0.015 pp | 0.00% +0.000 pp | USD32.16 +7.5% | 23 qtrs — |
| 48 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 250.0K +250.0K (+100.0%) | 8.64M +8.6M (+100.0%) | 0.28% +0.279 pp | 0.81% +0.808 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 49 | BANK OF NEW YORK MELLON CORP | 244.0K -4.9K (-2.0%) | 8.44M +1.7M (+24.6%) | 0.27% -0.009 pp | 0.00% +0.000 pp | USD25.69 +34.6% | 23 qtrs — |
| 50 | FRANKLIN RESOURCES INC | 240.2K +4.8K (+2.0%) | 8.30M +1.9M (+29.6%) | 0.27% +0.002 pp | 0.00% +0.000 pp | USD27.36 +26.4% | 2 qtrs — |
| 51 | INVESCO LTD. | 238.3K +114.1K (+91.9%) | 8.24M +4.9M (+143.8%) | 0.27% +0.129 pp | 0.00% +0.001 pp | USD30.27 +14.2% | 18 qtrs — |
| 52 | BARCLAYS PLC | 235.9K +54.7K (+30.2%) | 8.15M +2.4M (+42.1%) | 0.27% +0.062 pp | 0.00% +0.001 pp | USD28.03 +23.3% | 23 qtrs — |
| 53 | WCM INVESTMENT MANAGEMENT, LLC | 219.3K -14.1K (-6.1%) | 7.57M +1.2M (+19.2%) | 0.24% -0.019 pp | 0.02% +0.002 pp | USD25.62 +34.9% | 5 qtrs — |
| 54 | MILLENNIUM MANAGEMENT LLC | 208.5K +71.0K (+51.6%) | 7.21M +3.5M (+92.6%) | 0.24% +0.080 pp | 0.00% +0.001 pp | USD27.77 +24.5% | 8 qtrs — |
| 55 | AMERICAN CENTURY COMPANIES INC | 204.4K +17.7K (+9.5%) | 7.07M +2.0M (+39.1%) | 0.23% +0.017 pp | 0.00% +0.001 pp | USD24.10 +43.4% | 4 qtrs — |
| 56 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 202.4K +39.2K (+24.0%) | 7.00M +2.6M (+57.5%) | 0.23% +0.044 pp | 0.11% +0.038 pp | USD28.63 +20.7% | 2 qtrs — |
| 57 | WOODLINE PARTNERS LP | 201.7K +— (+0.0%) | 6.97M +1.5M (+27.0%) | 0.23% +0.000 pp | 0.03% +0.001 pp | USD30.29 +14.1% | 11 qtrs — |
| 58 | NICHOLAS INVESTMENT PARTNERS, LP | 192.4K +192.4K (+100.0%) | 6.65M +6.7M (+100.0%) | 0.21% +0.215 pp | 0.48% +0.485 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 59 | ALYESKA INVESTMENT GROUP, L.P. | 192.3K +192.3K (+100.0%) | 6.65M +6.6M (+100.0%) | 0.21% +0.215 pp | 0.02% +0.019 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 60 | UBS ASSET MANAGEMENT AMERICAS INC | 174.1K -27.3K (-13.6%) | 6.02M +538.2K (+9.8%) | 0.19% -0.034 pp | 0.00% +0.000 pp | USD29.37 +17.7% | 10 qtrs — |
| 61 | SCHRODER INVESTMENT MANAGEMENT GROUP | 171.3K -34.5K (-16.8%) | 5.91M +316.1K (+5.6%) | 0.19% -0.042 pp | 0.00% +0.000 pp | USD33.54 +3.1% | 8 qtrs — |
| 62 | ROYAL BANK OF CANADA | 165.3K -244.3K (-59.6%) | 5.72M -5.4M (-48.7%) | 0.19% -0.276 pp | 0.00% -0.001 pp | USD24.57 +40.7% | 21 qtrs — |
| 63 | VICTORY CAPITAL MANAGEMENT INC | 163.4K -65.5K (-28.6%) | 5.65M -579.1K (-9.3%) | 0.18% -0.077 pp | 0.00% -0.001 pp | USD27.57 +25.4% | 9 qtrs — |
| 64 | STEMPOINT CAPITAL LP | 161.7K -210.2K (-56.5%) | 5.59M -4.5M (-44.8%) | 0.18% -0.238 pp | 0.96% -1.069 pp | USD23.61 +46.4% | 8 qtrs — |
| 65 | SWISS NATIONAL BANK | 155.6K +2.8K (+1.8%) | 5.38M +1.2M (+29.4%) | 0.17% +0.001 pp | 0.00% +0.001 pp | USD27.38 +26.3% | 17 qtrs — |
| 66 | GREAT LAKES ADVISORS, LLC | 150.0K +150.0K (+100.0%) | 5.19M +5.2M (+100.0%) | 0.17% +0.170 pp | 0.04% +0.042 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 67 | CREATIVE PLANNING | 136.1K +3.2K (+2.4%) | 4.70M +1.1M (+30.1%) | 0.15% +0.002 pp | 0.00% +0.001 pp | USD21.41 +61.5% | 9 qtrs — |
| 68 | CITIGROUP INC | 127.1K +86.3K (+211.4%) | 4.39M +3.3M (+295.6%) | 0.14% +0.096 pp | 0.00% +0.001 pp | USD32.05 +7.9% | 25 qtrs — |
| 69 | RAFFERTY ASSET MANAGEMENT, LLC | 126.4K +33.2K (+35.7%) | 4.37M +1.8M (+72.3%) | 0.14% +0.036 pp | 0.02% +0.007 pp | USD27.35 +26.4% | 18 qtrs — |
| 70 | PLATINUM INVESTMENT MANAGEMENT LTD | 120.6K -46.3K (-27.7%) | 4.17M -372.5K (-8.2%) | 0.13% -0.054 pp | 0.96% +0.670 pp | USD21.74 +59.0% | 22 qtrs — |
| 71 | TWO SIGMA INVESTMENTS, LP | 113.8K +4.1K (+3.8%) | 3.94M +950.2K (+31.8%) | 0.13% +0.005 pp | 0.01% +0.001 pp | USD35.88 -3.7% | 16 qtrs — |
| 72 | — | 113.5K +113.5K (+100.0%) | 3.92M +3.9M (+100.0%) | 0.13% +0.127 pp | 0.14% +0.141 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 73 | NEUBERGER BERMAN GROUP LLC | 111.3K +111.3K (+100.0%) | 3.85M +3.8M (+100.0%) | 0.12% +0.124 pp | 0.00% +0.003 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 74 | RHUMBLINE ADVISERS | 107.6K -17.2K (-13.8%) | 3.72M +323.4K (+9.5%) | 0.12% -0.020 pp | 0.00% +0.000 pp | USD23.03 +50.1% | 23 qtrs — |
| 75 | ALLIANCEBERNSTEIN L.P. | 97.9K -3.0 (0.0%) | 3.38M +720.4K (+27.0%) | 0.11% +0.000 pp | 0.00% +0.000 pp | USD27.79 +24.4% | 23 qtrs — |
| 76 | HEALTHINVEST PARTNERS AB | 97.4K +97.4K (+100.0%) | 3.37M +3.4M (+100.0%) | 0.11% +0.109 pp | 1.07% +1.075 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 77 | MML INVESTORS SERVICES, LLC | 83.9K +2.6K (+3.2%) | 2.90M +687.7K (+31.1%) | 0.09% +0.002 pp | 0.01% +0.001 pp | USD27.44 +26.0% | 2 qtrs — |
| 78 | LEGAL & GENERAL GROUP PLC | 83.9K -8.1K (-8.8%) | 2.90M +397.6K (+15.9%) | 0.09% -0.010 pp | 0.00% +0.000 pp | USD26.69 +29.5% | 23 qtrs — |
| 79 | Y-INTERCEPT (HONG KONG) LTD | 81.0K +81.0K (+100.0%) | 2.80M +2.8M (+100.0%) | 0.09% +0.090 pp | 0.06% +0.063 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 80 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 75.9K +1.4K (+1.8%) | 2.63M +596.3K (+29.4%) | 0.08% +0.000 pp | 0.00% +0.001 pp | USD24.09 +43.5% | 23 qtrs — |
| 81 | SIO CAPITAL MANAGEMENT, LLC | 75.7K -48.5K (-39.0%) | 2.62M -762.3K (-22.6%) | 0.09% -0.055 pp | 0.41% -0.444 pp | USD31.57 +9.5% | 14 qtrs — |
| 82 | JANE STREET GROUP, LLC | 74.4K +64.0K (+615.4%) | 2.57M +2.3M (+808.9%) | 0.08% +0.071 pp | 0.00% +0.000 pp | USD33.54 +3.1% | 2 qtrs — |
| 83 | ASSETMARK, INC | 71.9K -4.3K (-5.6%) | 2.49M +412.3K (+19.9%) | 0.08% -0.006 pp | 0.01% +0.001 pp | USD32.53 +6.3% | 8 qtrs — |
| 84 | ALPS ADVISORS INC | 71.8K +29.6K (+70.3%) | 2.48M +1.3M (+116.4%) | 0.08% +0.032 pp | 0.01% +0.008 pp | USD30.84 +12.1% | 11 qtrs — |
| 85 | NEOS INVESTMENT MANAGEMENT LLC | 71.2K -3.1K (-4.2%) | 2.46M +439.8K (+21.8%) | 0.08% -0.004 pp | 0.01% -0.001 pp | USD21.65 +59.7% | 7 qtrs — |
| 86 | TEMA ETFS LLC | 70.1K -4.1K (-5.6%) | 2.42M +403.5K (+20.0%) | 0.08% -0.006 pp | 0.19% +0.020 pp | USD19.91 +73.6% | 5 qtrs — |
| 87 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 69.9K +3.4K (+5.1%) | 2.41M +605.5K (+33.5%) | 0.08% +0.003 pp | 0.00% +0.001 pp | USD28.10 +23.0% | 21 qtrs — |
| 88 | SEI INVESTMENTS CO | 68.7K +23.3K (+51.3%) | 2.38M +1.1M (+92.2%) | 0.08% +0.025 pp | 0.00% +0.001 pp | USD25.27 +36.8% | 4 qtrs — |
| 89 | AQR CAPITAL MANAGEMENT LLC | 68.2K +46.0K (+206.7%) | 2.36M +1.8M (+289.7%) | 0.08% +0.051 pp | 0.00% +0.001 pp | USD30.32 +14.0% | 11 qtrs — |
| 90 | DEKABANK DEUTSCHE GIROZENTRALE | 50.0K +— (+0.0%) | 2.35M +1.0M (+74.2%) | 0.06% +0.000 pp | 0.00% +0.002 pp | USD21.35 +61.9% | 21 qtrs — |
| 91 | XTX TOPCO LTD | 66.2K +66.2K (+100.0%) | 2.29M +2.3M (+100.0%) | 0.07% +0.075 pp | 0.06% +0.060 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 92 | BOOTHBAY FUND MANAGEMENT, LLC | 60.3K -14.5K (-19.4%) | 2.08M +48.7K (+2.4%) | 0.07% -0.017 pp | 0.03% +0.002 pp | USD23.00 +50.3% | 3 qtrs — |
| 93 | BRINKER CAPITAL INVESTMENTS, LLC | 58.4K +4.0K (+7.3%) | 2.02M +537.6K (+36.3%) | 0.07% +0.005 pp | 0.01% +0.003 pp | USD27.92 +23.8% | 8 qtrs — |
| 94 | LIDO ADVISORS, LLC | 55.5K +55.5K (+100.0%) | 1.91M +1.9M (+100.0%) | 0.06% +0.062 pp | 0.01% +0.006 pp | USD34.57 +0.0% | 1 qtrs NEW |
| 95 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 53.2K +21.4K (+67.3%) | 1.84M +973.8K (+112.5%) | 0.06% +0.024 pp | 0.00% +0.000 pp | USD30.17 +14.6% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 116 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF IDNA | 3.38% | 6.62M | 0.47% |
| 2 | Tema Oncology ETF CANC | 2.61% | 3.72M | 0.75% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 1.66% | 3.53M | 0.50% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 0.79% | 285.0K | 0.45% |
| 5 | State Street SPDR S&P Biotech ETF XBI | 0.79% | 85.84M | 0.35% |
| 6 | Virtus Biotech Clinical Trials ETF BBC | 0.79% | 452.2K | 0.65% |
| 7 | First Trust Innovation Leaders ETF ILDR | 0.57% | 1.73M | 0.75% |
| 8 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.47% | 1.32M | 0.39% |
| 9 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.37% | 4.22M | 0.40% |
| 10 | iShares Ageing Population UCITS ETF AGED.L | 0.28% | 2.45M | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
1.55M
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+1,550,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Stein Jeffrey | Director | P-Purchase | A | Common Stock | 50,000 | 32.96 | 1.65M | 54,281 | D | ↗ |
| 2026-01-30 | WHITE MICHAEL ANTHONY | Officer | A-Award | A | Stock Option (right to buy) | 190,000 | 32.19 | 6.12M | 190,000 | D | ↗ |
| 2026-01-30 | Snyder Douglas B. | Officer | A-Award | A | Stock Option (right to buy) | 130,000 | 32.19 | 4.18M | 130,000 | D | ↗ |
| 2026-01-30 | Ruiz Briseno Andres | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 32.19 | 2.58M | 80,000 | D | ↗ |
| 2026-01-30 | Hata Yujiro S | Director / Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 32.19 | 19.31M | 600,000 | D | ↗ |
| 2026-01-30 | DORMAN STUART | Officer | A-Award | A | Stock Option (right to buy) | 155,000 | 32.19 | 4.99M | 155,000 | D | ↗ |
| 2026-01-30 | Bleharski Joshua | Officer | A-Award | A | Stock Option (right to buy) | 170,000 | 32.19 | 5.47M | 170,000 | D | ↗ |
| 2026-01-30 | Beaupre Darrin | Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 32.19 | 5.63M | 175,000 | D | ↗ |
| 2025-11-28 | Snyder Douglas B. | Officer | A-Award | A | Common Stock | 1,041 | 16.91 | 17.6K | 2,080 | D | ↗ |
| 2025-11-28 | Ruiz Briseno Andres | Officer | A-Award | A | Common Stock | 1,253 | 16.91 | 21.2K | 26,466 | D | ↗ |
| 2025-06-27 | Bleharski Joshua | Officer | — | — | Stock Option (right to buy) | 250,000 | 20.05 | 5.01M | 0 | D | ↗ |
| 2025-06-24 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 21.78 | 435.6K | 20,000 | D | ↗ |
| 2025-06-24 | Stein Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 21.78 | 435.6K | 20,000 | D | ↗ |
| 2025-06-24 | ROSEN TERRY J | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 21.78 | 435.6K | 20,000 | D | ↗ |
| 2025-06-24 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 21.78 | 435.6K | 20,000 | D | ↗ |
| 2025-06-24 | MACKEY CATHERINE J | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 21.78 | 435.6K | 20,000 | D | ↗ |
| 2025-06-24 | Hampton Malcolm Garret | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 21.78 | 435.6K | 20,000 | D | ↗ |
| 2025-05-30 | Snyder Douglas B. | Officer | A-Award | A | Common Stock | 1,039 | 16.91 | 17.6K | 1,039 | D | ↗ |
| 2025-02-27 | WHITE MICHAEL ANTHONY | Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 20.24 | 3.74M | 185,000 | D | ↗ |
| 2025-02-27 | Snyder Douglas B. | Officer | A-Award | A | Stock Option (right to buy) | 33,000 | 20.24 | 667.9K | 33,000 | D | ↗ |
| 2025-02-27 | Ruiz Briseno Andres | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 20.24 | 1.52M | 75,000 | D | ↗ |
| 2025-02-27 | Hata Yujiro S | Director / Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 20.24 | 12.14M | 600,000 | D | ↗ |
| 2025-02-27 | DORMAN STUART | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 20.24 | 303.6K | 15,000 | D | ↗ |
| 2025-02-27 | Beaupre Darrin | Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 20.24 | 3.74M | 185,000 | D | ↗ |
| 2025-02-18 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 12,808 | 19.52 | 250.0K | 690,695 | D | ↗ |
| 2024-12-11 | DORMAN STUART | Officer | — | — | Stock Option (Right to Buy) | 170,000 | 27.45 | 4.67M | 0 | D | ↗ |
| 2024-11-29 | Ruiz Briseno Andres | Officer | A-Award | A | Common Stock | 682 | 23.26 | 15.9K | 25,213 | D | ↗ |
| 2024-09-26 | Snyder Douglas B. | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 30.50 | 4.27M | 140,000 | D | ↗ |
| 2024-09-18 | Snyder Douglas B. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-27 | Throne Jason | Officer | M-Exempt | A | Common Stock | 47,060 | 7.01 | 329.9K | 63,484 | — | ↗ |
| 2024-05-31 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 36.55 | 592.1K | 16,200 | — | ↗ |
| 2024-05-31 | Stein Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 36.55 | 592.1K | 16,200 | — | ↗ |
| 2024-05-31 | ROSEN TERRY J | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 36.55 | 592.1K | 16,200 | — | ↗ |
| 2024-05-31 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 36.55 | 592.1K | 16,200 | — | ↗ |
| 2024-05-31 | MACKEY CATHERINE J | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 36.55 | 592.1K | 16,200 | — | ↗ |
| 2024-05-31 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 36.55 | 592.1K | 16,200 | — | ↗ |
| 2024-05-31 | Hampton Malcolm Garret | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 36.55 | 592.1K | 16,200 | — | ↗ |
| 2024-05-29 | WHITE MICHAEL ANTHONY | Officer | M-Exempt | D | Stock Option (right to buy) | 28,500 | 12.86 | 366.5K | 64,000 | — | ↗ |
| 2024-05-16 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 34,433 | 4.31 | 148.4K | 712,320 | — | ↗ |
| 2024-05-15 | Hata Yujiro S | Director / Officer | S-Sale | D | Common Stock | 53,592 | 42.57 | 2.28M | 708,151 | — | ↗ |
| 2024-05-14 | Hata Yujiro S | Director / Officer | S-Sale | D | Common Stock | 54,408 | 41.60 | 2.26M | 680,190 | — | ↗ |
| 2024-03-01 | WHITE MICHAEL ANTHONY | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 46.22 | 6.47M | 140,000 | — | ↗ |
| 2024-03-01 | Throne Jason | Officer | A-Award | A | Stock Option (right to buy) | 125,500 | 46.22 | 5.80M | 125,500 | — | ↗ |
| 2024-03-01 | Ruiz Briseno Andres | Officer | A-Award | A | Stock Option (right to buy) | 85,000 | 46.22 | 3.93M | 85,000 | — | ↗ |
| 2024-03-01 | Hata Yujiro S | Director / Officer | A-Award | A | Stock Option (right to buy) | 480,000 | 46.22 | 22.19M | 480,000 | — | ↗ |
| 2024-03-01 | Beaupre Darrin | Officer | A-Award | A | Stock Option (right to buy) | 160,000 | 46.22 | 7.40M | 160,000 | — | ↗ |
| 2024-02-09 | Ruiz Briseno Andres | Officer | S-Sale | D | Common Stock | 2,000 | 46.02 | 92.0K | 24,531 | — | ↗ |
| 2024-02-09 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 23,557 | 4.31 | 101.5K | 701,444 | — | ↗ |
| 2024-02-08 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 75,815 | 4.31 | 326.8K | 753,702 | — | ↗ |
| 2024-02-01 | Hata Yujiro S | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 628 | 4.31 | 2.7K | 323,826 | — | ↗ |
| 2024-01-22 | Ruiz Briseno Andres | Officer | S-Sale | D | Common Stock | 2,000 | 42.03 | 84.1K | 26,531 | — | ↗ |
| 2024-01-16 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 62,739 | 4.31 | 270.4K | 740,626 | — | ↗ |
| 2024-01-12 | Ruiz Briseno Andres | Officer | S-Sale | D | Common Stock | 2,000 | 38.01 | 76.0K | 28,531 | — | ↗ |
| 2024-01-12 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 12,261 | 4.31 | 52.8K | 690,148 | — | ↗ |
| 2023-12-18 | Throne Jason | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 7.01 | 70.1K | 48,420 | — | ↗ |
| 2023-12-15 | Throne Jason | Officer | S-Sale | D | Common Stock | 10,000 | 35.04 | 350.4K | 0 | — | ↗ |
| 2023-12-15 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 75,000 | 4.31 | 323.3K | 752,887 | — | ↗ |
| 2023-12-14 | Ruiz Briseno Andres | Officer | S-Sale | D | Common Stock | 1,672 | 34.00 | 56.8K | 30,859 | — | ↗ |
| 2023-11-03 | Throne Jason | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,163 | 12.86 | 66.4K | 48,750 | — | ↗ |
| 2023-09-12 | Throne Jason | Officer | S-Sale | D | Common Stock | 500 | 30.01 | 15.0K | 0 | — | ↗ |
| 2023-09-05 | Throne Jason | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,737 | 12.86 | 22.3K | 54,913 | — | ↗ |
| 2023-09-01 | Throne Jason | Officer | M-Exempt | A | Common Stock | 2,100 | 12.86 | 27.0K | 2,100 | — | ↗ |
| 2023-09-01 | Ruiz Briseno Andres | Officer | S-Sale | D | Common Stock | 2,000 | 30.01 | 60.0K | 32,531 | — | ↗ |
| 2023-08-29 | Stone Paul A. | Officer | S-Sale | D | Common Stock | 5,000 | 28.87 | 144.4K | 9,303 | — | ↗ |
| 2023-08-21 | Stone Paul A. | Officer | S-Sale | D | Common Stock | 978 | 26.40 | 25.8K | 14,303 | — | ↗ |
| 2023-08-18 | Stone Paul A. | Officer | S-Sale | D | Common Stock | 3,822 | 26.38 | 100.8K | 15,281 | — | ↗ |
| 2023-08-16 | Stone Paul A. | Officer | S-Sale | D | Common Stock | 100 | 26.45 | 2.6K | 19,203 | — | ↗ |
| 2023-08-09 | Throne Jason | Officer | M-Exempt | A | Common Stock | 5,000 | 13.34 | 66.7K | 5,000 | — | ↗ |
| 2023-08-09 | Stone Paul A. | Officer | S-Sale | D | Common Stock | 2,500 | 25.05 | 62.6K | 19,303 | — | ↗ |
| 2023-07-10 | Throne Jason | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 12.86 | 64.3K | 58,750 | — | ↗ |
| 2023-07-01 | Ruiz Briseno Andres | Officer | — | D | Common Stock | 0 | 0.00 | — | 34,531 | — | ↗ |
| 2023-06-07 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 25.40 | 411.5K | 16,200 | — | ↗ |
| 2023-06-07 | Stein Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 25.40 | 411.5K | 16,200 | — | ↗ |
| 2023-06-07 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 25.40 | 411.5K | 16,200 | — | ↗ |
| 2023-06-07 | ROSEN TERRY J | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 25.40 | 411.5K | 16,200 | — | ↗ |
| 2023-06-07 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 25.40 | 411.5K | 16,200 | — | ↗ |
| 2023-06-07 | MACKEY CATHERINE J | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 25.40 | 411.5K | 16,200 | — | ↗ |
| 2023-06-07 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 25.40 | 411.5K | 16,200 | — | ↗ |
| 2023-06-07 | Hampton Malcolm Garret | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 25.40 | 411.5K | 16,200 | — | ↗ |
| 2023-06-01 | Throne Jason | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,553 | 7.01 | 24.9K | 62,905 | — | ↗ |
| 2023-05-31 | Throne Jason | Officer | M-Exempt | D | Stock Option (Right to Buy) | 432 | 7.01 | 3.0K | 66,458 | — | ↗ |
| 2023-05-22 | Throne Jason | Officer | S-Sale | D | Common Stock | 500 | 23.00 | 11.5K | 0 | — | ↗ |
| 2023-04-13 | Stone Paul A. | Officer | M-Exempt | A | Common Stock | 8,000 | 4.62 | 37.0K | 21,803 | — | ↗ |
| 2023-04-12 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 11,601 | 4.31 | 50.0K | 677,887 | — | ↗ |
| 2023-02-24 | WHITE MICHAEL ANTHONY | Officer | A-Award | A | Stock Option (right to buy) | 165,000 | 17.04 | 2.81M | 165,000 | — | ↗ |
| 2023-02-24 | Throne Jason | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 17.04 | 1.70M | 100,000 | — | ↗ |
| 2023-02-24 | Stone Paul A. | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 17.04 | 2.39M | 140,000 | — | ↗ |
| 2023-02-24 | Hata Yujiro S | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 17.04 | 6.82M | 400,000 | — | ↗ |
| 2023-02-24 | Beaupre Darrin | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 17.04 | 1.53M | 90,000 | — | ↗ |
| 2022-12-09 | Beaupre Darrin | Officer | — | D | Stock Option (right to buy) | 180,000 | 17.48 | 3.15M | — | — | ↗ |
| 2022-06-09 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 12.29 | 135.2K | 11,000 | — | ↗ |
| 2022-06-09 | Stein Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2022-06-09 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2022-06-09 | ROSEN TERRY J | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2022-06-09 | Morrison Scott W | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2022-06-09 | Kelley Susan L. | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2022-06-09 | Hampton Malcolm Garret | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2022-04-05 | MACKEY CATHERINE J | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 11.80 | 259.6K | 22,000 | — | ↗ |
| 2022-03-01 | WHITE MICHAEL ANTHONY | Officer | A-Award | A | Stock Option (right to buy) | 92,500 | 0.00 | — | 92,500 | — | ↗ |
| 2022-03-01 | Throne Jason | Officer | A-Award | D | Stock Option (Right to Buy) | 63,750 | 12.86 | 819.8K | 63,750 | — | ↗ |
| 2022-03-01 | Stone Paul A. | Officer | A-Award | A | Stock Option (right to buy) | 92,500 | 0.00 | — | 92,500 | — | ↗ |
| 2022-03-01 | Hata Yujiro S | Director / Officer | A-Award | A | Stock Option (right to buy) | 260,000 | 12.86 | 3.34M | 260,000 | — | ↗ |
| 2021-10-25 | WHITE MICHAEL ANTHONY | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-04 | Dillon Michael P. | Officer | M-Exempt | A | Common Stock | 1,500 | 11.08 | 16.6K | 80,289 | — | ↗ |
| 2021-09-08 | Dillon Michael P. | Officer | M-Exempt | A | Common Stock | 4,313 | 11.08 | 47.8K | 90,173 | — | ↗ |
| 2021-09-07 | Stone Paul A. | Officer | S-Sale | D | Common Stock | 2,500 | 27.42 | 68.5K | 12,944 | — | ↗ |
| 2021-09-07 | Dillon Michael P. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 116 | 4.31 | 499.96 | 66,119 | — | ↗ |
| 2021-09-02 | Dillon Michael P. | Officer | S-Sale | D | Common Stock | 10,000 | 25.09 | 250.9K | 78,789 | — | ↗ |
| 2021-08-09 | Dillon Michael P. | Officer | M-Exempt | A | Common Stock | 1,500 | 4.31 | 6.5K | 100,289 | — | ↗ |
| 2021-07-27 | Throne Jason | Officer | S-Sale | D | Common Stock | 10,000 | 25.17 | 251.7K | 0 | — | ↗ |
| 2021-07-27 | Dillon Michael P. | Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 6.92 | 34.6K | 39,500 | — | ↗ |
| 2021-07-06 | Throne Jason | Officer | S-Sale | D | Common Stock | 6,468 | 22.16 | 143.4K | 3,532 | — | ↗ |
| 2021-07-06 | Dillon Michael P. | Officer | M-Exempt | A | Common Stock | 1,500 | 6.92 | 10.4K | 100,289 | — | ↗ |
| 2021-06-17 | Dillon Michael P. | Officer | M-Exempt | A | Common Stock | 3,893 | 6.92 | 26.9K | 102,682 | — | ↗ |
| 2021-06-16 | Dillon Michael P. | Officer | M-Exempt | A | Common Stock | 1,107 | 6.92 | 7.7K | 99,896 | — | ↗ |
| 2021-06-10 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 21.66 | 238.3K | 11,000 | — | ↗ |
| 2021-06-10 | Stein Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 21.66 | 238.3K | 11,000 | — | ↗ |
| 2021-06-10 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 21.66 | 238.3K | 11,000 | — | ↗ |
| 2021-06-10 | ROSEN TERRY J | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 21.66 | 238.3K | 11,000 | — | ↗ |
| 2021-06-10 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 21.66 | 238.3K | 11,000 | — | ↗ |
| 2021-06-10 | Hampton Malcolm Garret | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 21.66 | 238.3K | 11,000 | — | ↗ |
| 2021-06-07 | Dillon Michael P. | Officer | M-Exempt | A | Common Stock | 1,500 | 6.92 | 10.4K | 100,289 | — | ↗ |
| 2021-05-28 | Stone Paul A. | Officer | A-Award | A | Common Stock | 859 | 11.36 | 9.8K | 13,803 | — | ↗ |
| 2021-05-11 | Dillon Michael P. | Officer | S-Sale | D | Common Stock | 5,000 | 20.22 | 101.1K | 98,789 | — | ↗ |
| 2021-02-24 | Throne Jason | Officer | A-Award | A | Stock Option (right to buy) | 52,500 | 19.52 | 1.02M | 52,500 | — | ↗ |
| 2021-02-24 | Stone Paul A. | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 19.52 | 1.56M | 80,000 | — | ↗ |
| 2021-02-24 | Lackner Mark | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 19.52 | 878.4K | 45,000 | — | ↗ |
| 2021-02-24 | Hata Yujiro S | Director / Officer | A-Award | A | Stock Option (right to buy) | 195,000 | 19.52 | 3.81M | 195,000 | — | ↗ |
| 2021-02-24 | Dillon Michael P. | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 19.52 | 1.56M | 80,000 | — | ↗ |
| 2021-02-12 | Kelley Susan L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-10 | Lackner Mark | Officer | M-Exempt | D | Stock Option (right to buy) | 596 | 6.98 | 4.2K | 33,014 | — | ↗ |
| 2021-02-09 | Lackner Mark | Officer | S-Sale | D | Common Stock | 1,104 | 21.05 | 23.2K | 0 | — | ↗ |
| 2021-02-09 | Dillon Michael P. | Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 6.92 | 34.6K | 57,500 | — | ↗ |
| 2021-02-08 | Lackner Mark | Officer | M-Exempt | D | Stock Option (right to buy) | 300 | 6.98 | 2.1K | 34,714 | — | ↗ |
| 2021-02-02 | BVF PARTNERS L P/IL | — | S-Sale | D | Common Stock, $0.0001 par value | 16,850 | 18.00 | 303.3K | 1,188,131 | — | ↗ |
| 2021-01-26 | Lackner Mark | Officer | M-Exempt | D | Stock Option (right to buy) | 377 | 4.62 | 1.7K | 61,760 | — | ↗ |
| 2020-12-22 | Hata Yujiro S | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 8,000 | 4.31 | 34.5K | 486,055 | — | ↗ |
| 2020-12-18 | Dillon Michael P. | Officer | M-Exempt | A | Common Stock | 7,750 | 4.31 | 33.4K | 98,789 | — | ↗ |
| 2020-12-11 | Stone Paul A. | Officer | J-Other | A | Common Stock | 444 | 0.00 | — | 15,444 | — | ↗ |
| 2020-12-04 | Throne Jason | Officer | S-Sale | D | Common Stock | 400 | 14.66 | 5.9K | 1,579 | — | ↗ |
| 2020-11-11 | 5AM Ventures IV, L.P. | 10% Owner | S-Sale | D | Common Stock | 657,117 | 13.66 | 8.98M | 2,187,428 | — | ↗ |
| 2020-07-01 | Throne Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 13.34 | 1.00M | 75,000 | — | ↗ |
| 2020-06-30 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 1,521 | 13.32 | 20.3K | 1,667,420 | — | ↗ |
| 2020-06-26 | Hampton Malcolm Garret | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 14.42 | 317.2K | 22,000 | — | ↗ |
| 2020-06-22 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 1,354 | 13.93 | 18.9K | 237,394 | — | ↗ |
| 2020-06-19 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 52,443 | 14.39 | 754.6K | 1,655,375 | — | ↗ |
| 2020-06-18 | BVF PARTNERS L P/IL | 10% Owner | — | D | Common Stock, $0.0001 par value | 0 | 0.00 | — | 1,602,932 | — | ↗ |
| 2020-06-17 | Stone Paul A. | Officer | S-Sale | D | Common Stock | 600 | 19.95 | 12.0K | 15,000 | — | ↗ |
| 2020-06-17 | Lackner Mark | Officer | S-Sale | D | Common Stock | 373 | 19.91 | 7.4K | 0 | — | ↗ |
| 2020-06-16 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 12.84 | 141.2K | 11,000 | — | ↗ |
| 2020-06-16 | Stein Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 12.84 | 141.2K | 11,000 | — | ↗ |
| 2020-06-16 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 12.84 | 141.2K | 11,000 | — | ↗ |
| 2020-06-16 | ROSEN TERRY J | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 12.84 | 141.2K | 11,000 | — | ↗ |
| 2020-06-16 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 12.84 | 141.2K | 11,000 | — | ↗ |
| 2020-06-16 | Lackner Mark | Officer | S-Sale | D | Common Stock | 6,750 | 14.93 | 100.8K | 0 | — | ↗ |
| 2020-06-04 | Throne Jason | Officer | S-Sale | D | Common Stock | 2,205 | 8.66 | 19.1K | 0 | — | ↗ |
| 2020-06-02 | Lackner Mark | Officer | S-Sale | D | Common Stock | 408 | 8.55 | 3.5K | 437 | — | ↗ |
| 2020-04-15 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 47,564 | 4.31 | 205.0K | 658,286 | — | ↗ |
| 2020-03-30 | Stone Paul A. | Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 4.62 | 23.1K | 140,932 | — | ↗ |
| 2020-02-21 | Stone Paul A. | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 6.92 | 553.6K | 80,000 | — | ↗ |
| 2020-02-21 | Lackner Mark | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 6.92 | 276.8K | 40,000 | — | ↗ |
| 2020-02-21 | Hata Yujiro S | Officer | A-Award | A | Stock Option (right to buy) | 215,000 | 6.92 | 1.49M | 215,000 | — | ↗ |
| 2020-02-21 | Hambleton Julie | Officer | A-Award | A | Stock Option (right to buy) | 62,500 | 6.92 | 432.5K | 62,500 | — | ↗ |
| 2020-02-21 | Dillon Michael P. | Officer | A-Award | A | Stock Option (right to buy) | 62,500 | 6.92 | 432.5K | 62,500 | — | ↗ |
| 2019-12-17 | YARNO WENDY L | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 7.36 | 161.9K | 22,000 | — | ↗ |
| 2019-10-09 | Throne Jason | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 7.01 | 525.8K | 75,000 | — | ↗ |
| 2019-09-24 | Stein Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 1,250 | 9.15 | 11.4K | 1,250 | — | ↗ |
| 2019-09-24 | SHANNON TIMOTHY M | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 9.15 | 100.7K | 11,000 | — | ↗ |
| 2019-09-24 | ROSEN TERRY J | Director | A-Award | A | Stock Option (right to buy) | 1,250 | 9.15 | 11.4K | 1,250 | — | ↗ |
| 2019-09-24 | Morrison Scott W | Director | A-Award | A | Stock Option (right to buy) | 1,250 | 9.15 | 11.4K | 1,250 | — | ↗ |
| 2019-09-24 | DIEKMAN JOHN D | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 9.15 | 100.7K | 11,000 | — | ↗ |
| 2019-07-30 | Hata Yujiro S | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 4.31 | 64.7K | 610,722 | — | ↗ |
| 2019-07-26 | Stone Paul A. | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 4.62 | 46.2K | 145,932 | — | ↗ |
| 2019-07-26 | Hager Jeffrey | Officer | M-Exempt | A | Common Stock | 5,197 | 4.31 | 22.4K | 127,853 | — | ↗ |
| 2019-07-10 | Hager Jeffrey | Officer | M-Exempt | D | Stock Option (right to buy) | 7,145 | 4.31 | 30.8K | 33,275 | — | ↗ |
| 2019-06-19 | Hager Jeffrey | Officer | M-Exempt | A | Common Stock | 8,628 | 4.31 | 37.2K | 115,511 | — | ↗ |
| 2019-05-28 | Stone Paul A. | Officer | C-Conversion | D | Series B Preferred Stock | 24,101 | 0.00 | — | 0 | — | ↗ |
| 2019-05-28 | SHANNON TIMOTHY M | Director | P-Purchase | A | Common Stock | 400,000 | 10.00 | 4.00M | 2,660,713 | — | ↗ |
| 2019-05-28 | DIEKMAN JOHN D | Director | C-Conversion | D | Series A Preferred Stock | 71,745 | 0.00 | — | 0 | — | ↗ |
| 2019-05-28 | CANAAN X L.P. | 10% Owner | C-Conversion | D | Series B Preferred Stock | 602,549 | 0.00 | — | 0 | — | ↗ |
| 2019-05-28 | Alexandria Venture Investments, LLC | 10% Owner | C-Conversion | D | Series B preferred stock | 772,499 | 0.00 | — | 0 | — | ↗ |
| 2019-05-28 | 5AM Ventures IV, L.P. | 10% Owner | C-Conversion | A | Common Stock | 578,447 | 0.00 | — | 2,604,545 | — | ↗ |
| 2019-05-22 | Stone Paul A. | Officer | — | D | Stock Option (right to buy) | 155,932 | 4.62 | 720.4K | 0 | — | ↗ |
| 2019-05-22 | Stein Jeffrey | Director | — | D | Common Stock | 0 | 0.00 | — | 4,281 | — | ↗ |
| 2019-05-22 | Schroeder Thilo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | SHANNON TIMOTHY M | Director | — | I | Series A Preferred Stock | 1,658,164 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | ROSEN TERRY J | Director | — | D | Common Stock | 0 | 0.00 | — | 16,346 | — | ↗ |
| 2019-05-22 | Morrison Scott W | Director | — | D | Stock Option (right to buy) | 16,346 | 4.62 | 75.5K | 0 | — | ↗ |
| 2019-05-22 | Lackner Mark | Officer | — | D | Stock Option (right to buy) | 39,000 | 6.98 | 272.2K | 0 | — | ↗ |
| 2019-05-22 | Hata Yujiro S | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 595,722 | — | ↗ |
| 2019-05-22 | Hambleton Julie | Officer | — | D | Stock Option (right to buy) | 23,400 | 11.08 | 259.3K | 0 | — | ↗ |
| 2019-05-22 | Hager Jeffrey | Officer | — | D | Stock Option (right to buy) | 17,550 | 11.08 | 194.5K | 0 | — | ↗ |
| 2019-05-22 | Dillon Michael P. | Officer | — | D | Common Stock | 0 | 0.00 | — | 91,039 | — | ↗ |
| 2019-05-22 | DIEKMAN JOHN D | Director | — | I | Common Stock | 0 | 0.00 | — | 304,200 | — | ↗ |
| 2019-05-22 | CANAAN X L.P. | 10% Owner | — | D | Series A Preferred Stock | 1,658,164 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | Alexandria Venture Investments, LLC | 10% Owner | — | D | Series A preferred stock | 307,066 | 0.00 | — | 0 | — | ↗ |
| 2019-05-22 | 5AM Ventures IV, L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 304,200 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-1.22M
Shares Outstanding
87.81M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Yujiro S. Hata President and Chief Executive Officer | 700.0K | — | — | 8.42M | 378.0K | 15.8K | 9.51M | 88.50% | ↗ |
| 2 | 2025 | Joshua Bleharski, Ph.D. Chief Financial Officer | 333.3K | 150.0K | — | 3.46M | 186.0K | 14.0K | 4.15M | 83.52% | ↗ |
| 3 | 2025 | Darrin M. Beaupre, M.D., Ph.D. Chief Medical Officer | 526.5K | — | — | 2.60M | 196.0K | 15.8K | 3.33M | 77.86% | ↗ |
| 4 | 2025 | Michael A. White, Ph.D. Chief Scientific Officer | 519.0K | — | — | 2.60M | 193.5K | 15.8K | 3.32M | 78.09% | ↗ |
| 5 | 2025 | Andres Ruiz Briseno Chief Accounting Officer | 417.0K | — | — | 1.05M | 168.0K | 15.8K | 1.65M | 63.66% | ↗ |
| 6 | 2025 | Douglas B. Snyder Chief Legal Officer | 440.0K | — | — | 463.0K | 164.0K | 64.5K | 1.13M | 40.92% | ↗ |
| 7 | 2024 | Yujiro S. Hata President and Chief Executive Officer | 646.0K | — | — | 15.95M | 323.0K | 15.6K | 16.93M | 94.18% | ↗ |
| 8 | 2024 | Darrin M. Beaupre, M.D., Ph.D. Chief Medical Officer | 501.5K | — | — | 5.32M | 228.1K | 15.6K | 6.06M | 87.70% | ↗ |
| 9 | 2024 | Michael A. White, Ph.D. Chief Scientific Officer | 489.5K | — | — | 4.65M | 223.3K | 15.6K | 5.38M | 86.46% | ↗ |
| 10 | 2024 | Jason S. Throne Former Chief Legal Officer | 286.2K | — | — | 4.17M | — | 14.8K | 4.47M | 93.27% | ↗ |
| 11 | 2024 | Stuart C. Dorman Chief Commercial Officer | 41.7K | 100.0K | — | 3.26M | 20.0K | 150.00 | 3.42M | 95.27% | ↗ |
| 12 | 2024 | Andres Ruiz Briseno Chief Accounting Officer | 382.5K | — | — | 2.82M | 133.9K | 15.6K | 3.36M | 84.15% | ↗ |
| 13 | 2023 | Yujiro S. Hata President and Chief Executive Officer | 598.0K | — | — | 5.08M | 299.0K | 15.0K | 6.00M | 84.79% | ↗ |
| 14 | 2023 | Michael A. White, Ph.D. Chief Scientific Officer | 462.0K | — | — | 2.10M | 184.8K | 15.0K | 2.76M | 76.01% | ↗ |
| 15 | 2023 | Paul A. Stone. Former Chief Financial Officer | 432.0K | — | — | 1.78M | — | 14.8K | 2.23M | 79.93% | ↗ |
| 16 | 2023 | Jason S. Throne Chief Legal Officer | 417.0K | — | — | 1.27M | 166.8K | 15.0K | 1.87M | 67.97% | ↗ |
| 17 | 2023 | Jason S. Throne Former Chief Legal Officer | 417.0K | — | — | 1.27M | 166.8K | 15.0K | 1.87M | 67.97% | ↗ |
| 18 | 2023 | Darrin M. Beaupre, MD., Ph.D. Chief Medical Officer | 473.0K | — | — | 1.14M | 189.2K | 3.4K | 1.81M | 63.21% | ↗ |
| 19 | 2023 | Darrin M. Beaupre, M.D., Ph.D. Chief Medical Officer | 473.0K | — | — | 1.14M | 189.2K | 3.4K | 1.81M | 63.21% | ↗ |
| 20 | 2023 | Andres Ruiz Briseno Chief Accounting Officer | 345.0K | — | — | 927.4K | 125.1K | 15.0K | 1.41M | 65.66% | ↗ |
| 21 | 2023 | Andres Ruiz Briseno Senior Vice President, Head of Finance and Investor Relations | 345.0K | — | — | 927.4K | 125.1K | 15.0K | 1.41M | 65.66% | ↗ |
| 22 | 2022 | Yujiro S. Hata President and Chief Executive Officer | 570.0K | — | — | 2.48M | 270.8K | 11.0K | 3.33M | 74.40% | ↗ |
| 23 | 2022 | Darrin M. Beaupre, M.D., Ph.D. Chief Medical Officer | 52.5K | 100.0K | — | 2.38M | — | 150.00 | 2.53M | 93.97% | ↗ |
| 24 | 2022 | Darrin M. Beaupre, MD., Ph.D. Chief Medical Officer | 52.5K | 100.0K | — | 2.38M | — | 150.00 | 2.53M | 93.97% | ↗ |
| 25 | 2022 | Michael White, Ph.D. Chief Scientific Officer | 440.0K | — | — | 880.6K | 169.8K | 4.0K | 1.49M | 58.93% | ↗ |
| 26 | 2022 | Michael A. White, Ph.D. Chief Scientific Officer | 440.0K | — | — | 880.6K | 169.8K | 4.0K | 1.49M | 58.93% | ↗ |
| 27 | 2022 | Paul A. Stone. Former Chief Financial Officer | 419.0K | — | — | 880.6K | 161.7K | 11.0K | 1.47M | 59.81% | ↗ |
| 28 | 2021 | Yujiro S. Hata President and Chief Executive Officer | 543.6K | — | — | 3.05M | 244.6K | 10.5K | 3.85M | 79.25% | ↗ |
| 29 | 2021 | Michael White, Ph.D. Senior Vice President and Chief Scientific Officer, Head of Research | 80.6K | 180.0K | — | 3.32M | — | 375.00 | 3.58M | 92.72% | ↗ |
| 30 | 2021 | Michael A. White, Ph.D. Chief Scientific Officer | 80.6K | 180.0K | — | 3.32M | — | 375.00 | 3.58M | 92.72% | ↗ |
| 31 | 2021 | Michael White, Ph.D. Chief Scientific Officer | 80.6K | 180.0K | — | 3.32M | — | 375.00 | 3.58M | 92.72% | ↗ |
| 32 | 2021 | Michael Dillon, Ph.D. Former Senior Vice President and Chief Scientific Officer, Head of Research | 385.8K | — | — | 1.25M | — | 379.1K | 2.02M | 62.06% | ↗ |
| 33 | 2021 | Paul A. Stone, J.D. Senior Vice President and Chief Financial Officer | 394.0K | — | — | 1.25M | 146.9K | 10.5K | 1.80M | 69.41% | ↗ |
| 34 | 2021 | Paul A. Stone. Former Chief Financial Officer | 394.0K | — | — | 1.25M | 146.9K | 10.5K | 1.80M | 69.41% | ↗ |
| 35 | 2020 | Yujiro S. Hata President and Chief Executive Officer | 509.8K | — | — | 1.07M | 191.2K | 10.4K | 1.78M | 59.99% | ↗ |
| 36 | 2020 | Jason S. Throne, J.D. Senior Vice President, General Counsel, and Corporate Secretary | 332.5K | — | — | 738.2K | 89.5K | 3.6K | 1.16M | 63.43% | ↗ |
| 37 | 2020 | Paul A. Stone, J.D. Senior Vice President and Chief Financial Officer | 374.5K | — | — | 396.8K | 123.6K | 10.4K | 905.3K | 43.84% | ↗ |
| 38 | 2020 | Michael Dillon, Ph.D. Former Senior Vice President and Chief Scientific Officer, Head of Research | 371.0K | — | — | 310.0K | 122.4K | 1.8K | 805.3K | 38.50% | ↗ |
| 39 | 2019 | Yujiro Hata President and Chief Executive Officer | 457.2K | — | — | 1.40M | 154.9K | 10.2K | 2.02M | 69.21% | ↗ |
| 40 | 2019 | Yujiro S. Hata President and Chief Executive Officer | 457.2K | — | — | 1.40M | 154.9K | 10.2K | 2.02M | 69.21% | ↗ |
| 41 | 2019 | Julie Hambleton, M.D. Senior Vice President and Chief Medical Officer, Head of Development | 387.1K | — | — | 181.0K | 108.5K | 10.2K | 686.7K | 26.35% | ↗ |
| 42 | 2019 | Michael Dillon, Ph.D. Senior Vice President and Chief Scientific Officer, Head of Research | 338.9K | — | — | 226.2K | 95.5K | 10.2K | 670.8K | 33.72% | ↗ |
| 43 | 2019 | Paul A. Stone, J.D. Senior Vice President and Chief Financial Officer | 327.3K | — | — | 181.0K | 103.0K | 1.8K | 613.0K | 29.52% | ↗ |
| 44 | 2018 | Yujiro Hata President and Chief Executive Officer | 420.0K | — | — | 1.69M | 147.0K | 8.0K | 2.26M | 74.59% | ↗ |
| 45 | 2018 | Julie Hambleton, M.D. Senior Vice President and Chief Medical Officer, Head of Development | 218.8K | — | — | 512.2K | 65.6K | 1.1K | 797.6K | 64.22% | ↗ |
| 46 | 2018 | Michael Dillon, Ph.D. Senior Vice President and Chief Scientific Officer, Head of Research | 315.0K | — | — | 244.0K | 94.5K | 4.5K | 658.0K | 37.09% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yujiro S. Hata | Founder, President, Chief Executive Officer & Director | 1M | male |
| Darrin Beaupre | Chief Medical Officer | 745.2K | — |
| Michael A. White | Chief Scientific Officer | 728.4K | — |
| Joshua Bleharski | Chief Financial Officer | 551.4K | — |
| Andres Ruiz Briseno | Chief Accounting Officer | 532.0K | male |
| Stuart Dorman | Chief Commercial Officer | 161.8K | male |
| Jasgit Sachdev | Senior Vice President of Late Phase Clinical Development & Strategy | — | — |
| Daniel A. Simon | Chief Business Officer | — | male |
| Mick O'Quigley | Senior Vice President of Medical Writing & Project Management | — | male |
| Paul A. Barsanti | Chief Technology Officer | — | — |
| Theodora Ross | Chief Development Officer | — | — |
| Douglas Snyder | Chief Legal Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IDYA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
